Coenzyme Q10 deficiency in elderly: Can nutritional supplementation play a role? Mini review

Abstract

Coenzyme Q10 (CoQ10), an important mitochondrial redox component, plays a pivotal role in cellular energy production; moreover, it is the only lipid-soluble antioxidant endogenously synthesized in humans. Given its function and physiological importance, it is not surprising that CoQ10 deficiency may result in several diseases. With aging, humans begin to lose the ability to synthesize CoQ10 from food, resulting in reduced serum levels of CoQ10 and contributing to aging-associated symptoms. Poor eating habits, infections, stress and also some drugs, as beta blockers, antihypertensive agents and statns, may reduce serum levels of CoQ10. Dietary supplementation has been proposed as key strategy to increase CoQ10 availability, improving health status in elderly; however CoQ10 is not approved by U.S. Food and Drug Administration for the treatment of any medical condition and it is sold only as a dietary supplement. Aim of the study was to examine the latest relevant evidences on potential benefits of CoQ10 nutritional supplement and its implication in improving health status in elderly. There is evidence that, in elderly, oral administration of CoQ10 reduces oxidative stress and inflammatory markers and reduces cardiovascular mortality; in diabetics CoQ10 treatment improves insulin sensitivity and decreases glycated hemoglobin. Therapeutic benefit from CoQ10 supplementation has also been obtained in neurodegenerative diseases as Parkinson’s, Alzheimer’s and Huntington's diseases. CoQ10 supplements could be useful in several aging- related clinical conditions; however, well standardized long-term and larger further studies are needed. 

Keywords

• coenzyme Q10,elderly,supplementation

References

1. [1] Littarru GP, Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol 2007;37:31-7.
2. [2] Kawamukai M. Biosynthesis of coenzyme Q in eukaryotes. Biosci Biotechnol Biochem 2016;80:23-33.
3. [3] Kalen A, Appelkvist EL, Dallner G. Age-related changes in the lipid compositions of rat and human tissues. Lipids 1989;24:579-84.
4. [4] Saini R. Coenzyme Q10: the essential nutrient. J Pharm Bioallied Sci 2011;3:466-7.
5. [5] Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007;49:2231-7.
6. [6] Garrido-Maraver J, Cordero MD, Oropesa-Ávila M, Fernández Vega A, de la Mata M, Delgado Pavón A, et al. Coenzyme q10 therapy. Mol Syndromol 2014;5:187-97.
7. [7] Braillon A. Coenzyme Q10 and statin-induced myopathy--II. Mayo Clinic Proc 2015;90:420.
8. [8] Pravst I, Zmitek K, Zmitek J. Coenzyme Q10 contents in foods and fortification strategies. Critical Rev Food Sc iNutr 2010;50:269-80.

9. [9] Žmitek K, Pogačnik T, Mervic L, Žmitek J, Pravst I. The effect of dietary intake of coenzyme Q10 on skin parameters and condition: results of a randomised, placebo-controlled, double-blind study. Biofactors 2017;43:132-40.
10. [10] De Luca C, Mikhal'chik EV, Suprun MV, Papacharalambous M, Truhanov AI, Korkina LG. Skin antiageing and systemic redox effects of supplementation with marine collagen peptides and plant-derived antioxidants: a single-blind case-control clinical study. Oxid Med Cell Longev 2016;2016:4389410.
11. [11] Rona C, Vailati F, Berardesca E. The cosmetic treatment of wrinkles. J Cosmet Dermat 2004;3:26-34.
12. [12] Chiu A, Kimball A. Topical vitamins, minerals and botanical ingredients as modulators of environmental and chronological skin damage. Br J Dermatol 2003;149:681-91.
13. [13] Johansson P, Dahlström Ö, Dahlström U, Alehagen U. Improved health-related quality of life, and more days out of hospital with supplementation with selenium and coenzyme Q10 combined. Results from a double blind, placebo-controlled prospective study. J Nutr Health Aging 2015;19:870-7.
14. [14] González-Guardia L, Yubero-Serrano EM, Delgado-Lista J, Perez-Martinez P, Garcia- Rios A, Marin C, et al. Effects of the Mediterranean diet supplemented with coenzyme q10 onmetabolomic profiles in elderly men and women. J Gerontol A Biol Sci Med Sci 2015;70:78-84.
15. [15] Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ, Pella D, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. JACC Heart Fail 2014;2:641-49.
16. [16] Sander S, Coleman CI, Patel AA, Kluger J, White CM. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail 2006;12:464-72.
17. [17] Onur S, Niklowitz P, Jacobs G, Lieb W, Menke T, Döring F. Association between serum level of ubiquinol and NT-proBNP, a marker for chronic heart failure, inhealthy elderly subjects. Biofactors 2015;41:35-43.
18. [18] Johansson P, Dahlström Ö, Dahlström U, Alehagen U. Effect of selenium and Q10 on the cardiac biomarker NT-proBNP. Scand Cardiovasc J 2013;47:281-8.
19. [19] Alehagen U, Johansson P, Björnstedt M, Rosén A, Dahlström U. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzymeQ10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. Int J Cardiol 2013;167:1860-6.
20. [20] Alehagen U,Alexander J, Aaseth J. Supplementation with selenium and coenzyme Q10 reduces cardiovascular mortality in elderly with low selenium status. A secondary analysis of a randomised clinical trial. PLoS One 2016;11:e0157541.
21. [21] Alehagen U, Aaseth J, Johansson P. Reduced cardiovascular mortality 10 years after supplementation with selenium and coenzyme Q10 for four years: follow-up results of a prospective randomized double-blind placebo-controlled trial in elderly citizens. PLoS One 2015;10:e0141641.
22. [22] Lee BJ, Huang YC, Chen SJ, Lin PT. Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with coronary artery disease. Nutrition 2012;28:250-5.
23. [23] Lee BJ, Huang YC, Chen SJ, Lin PT. Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease. Nutrition 2012;28:767-72.
24. [24] Mirhashemi SM, Najafi V, Raygan F, Asemi Z. The effects of coenzyme Q10 supplementation on cardiometabolic markers in overweight type 2 diabetic patients with stable myocardial infarction: a randomized, double-blind, placebo-controlled trial. ARYA Atheroscler 2016;12:158-65.
25. [25] Lee BJ, Tseng YF, Yen CH, Lin PT. Effects of coenzymeQ10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial. Nutr J 2013;12(1):142.
26. [26] Lonnrot K, PorstiI, Alho H, Wu X, Hervonen A, Tolvanen JP. Control of arterial tone after long-term coenzyme Q10 supplementation in senescent rats. Br J Pharmacol 1998;124:1500-6.
27. [27] Langsjoen H, Langsjoen P, Willis R, Willis R, Folkers K. Usefulness of coenzyme Q10 in clinical cardiology: a long-term study. Mol Aspects Med 1994;15Suppl:s165-75.
28. [28] Bagheri Nesami N, Mozaffari-Khosravi H, Najarzadeh A, Salehifar E. The Effect of Coenzyme Q10 Supplementation on Pro-Inflammatory Factors and Adiponectin in Mildly hypertensive patients: a randomized, double-blind, placebo-controlled trial. Int J Vitam Nutr Res 2015;85:156-64.
29. [29] Cicero AF, Morbini M, Rosticci M, D'Addato S, Grandi E, Borghi C. Middle-Term dietary supplementation with red yeast rice plus coenzyme Q10 improves lipid pattern, endothelial reactivity and arterial stiffness in moderately hypercholesterolemic subjects. Ann Nutr Metab 2016;68:213-9.
30. [30] Barrat E, Zaïr Y,Ogier N, Housez B,Vergara C, Maudet C, et al. A combined natural supplement lowers LDL cholesterol in subjects with moderate untreated hypercholesterolemia: a randomized placebo-controlled trial. Int J Food Sci Nutr 2013;64:882-9.
31. [31] Hobbs T, Caso R, McMahon D, Nymark M.A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study. Altern Ther Health Med 2014;20:18-23.
32. [32] Skarlovnik A, Janić M, Lunder M, Turk M, ŠabovičM. Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study. Med Sci Monit 2014;20:2183-8.
33. [33] Fedacko J, Pella D, Fedackova P, Hänninen O, Tuomainen P, Jarcuska P, et al. Coenzyme Q(10) and selenium in statin-associated myopathy treatment. Can J Physiol Pharmacol 2013;91:165-70.
34. [34] Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis 2015;238:329-35.
35. [35] Bogsrud MP, Langslet G, OseL, Arnesen KE, SmStuen MC, Malt UF, et al. No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy. Scand Cardiovasc J 2013;47:80-7.
36. [36] Zhou XJ, Rakheja D, Yu X, Saxena R, Vaziri ND, Silva FG. The aging kidney. Kidney Int 2008;74:710-20.
37. [37] O'Sullivan ED,Hughes J, Ferenbach DA. Renal Aging: causes and consequences. J Am Soc Nephrol 2017;28:407-20.
38. [38] O’Hare AM, Choi AI, Bertenthal D, Bacchetti P, Garg AX, Kaufman JS, et al. Age affects outcomes in chronic kidney disease. J Am Soc Nephrol 2007;18:2758-65.
39. [39] Cottone S, Lorito MC, Riccobene R, Nardi E, Mulè G, Buscemi S, et al. Oxidative stress, inflammation and cardiovascular disease in chronic renal failure. J Nephrol 2008;21:175-9.
40. [40] Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006;48:752-60.
41. [41] Gokbel H, Turk S, Okudan N, Atalay H, Belviranli M, Gaipov A, et al. Effects of coenzyme Q10 supplementation on exercise performance and markers of oxidative stress in hemodialysis patients: a double-blind placebo-controlled crossover trial. Am J Ther 2016;23:e1736-43.
42. [42] Yeung CK, Billings FT 4th, Claessens AJ, Roshanravan B, Linke L,Sundell MB, et al. Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress. BMC Nephrol 2015;16:183.
43. [43] Barden A, O'Callaghan N, Burke V, Mas E, Beilin LJ, Fenech M, et al. n-3 fatty acid supplementation and leukocyte telomere length in patients with chronic kidney disease. Nutrients 2016;8:175.
44. [44] Pirro M, Mannarino MR, Bianconi V, Simental-Mendía LE, Bagaglia F, Mannarino E, et al. The effects of a nutraceutical combination on plasma lipids and glucose: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2016;110:76-88.
45. [45] Mehrdadi P, KolahdouzMohammadi R, Alipoor E, Eshraghian MR, Esteghamati A, Hosseinzadeh-Attar MJ. The Effect of coenzyme Q10 supplementation on Ccrculating levels of novel adipokine adipolin/CTRP12 in overweight and obese patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2017;125:156-62.
46. [46] Moazen M, Mazloom Z, Ahmadi A, Dabbaghmanesh MH, Roosta S. Effect of coenzyme Q10 on glycaemic control, oxidative stress and adiponectin in type 2 diabetes. J Pak Med Assoc 2015;65:404-8.
47. [47] Kolahdouz Mohammadi R, Hosseinzadeh-Attar MJ, Eshraghian MR, Nakhjavani M, Khorami E, Esteghamati A. The effect of coenzyme Q10 supplementation on metabolic status of type 2 diabetic patients. Minerva Gastroenterol Dietol 2013;59:231-6.
48. [48] Domanico D, Fragiotta S, Cutini A, Carnevale C, Zompatori L, Vingolo EM. Circulating levels of reactive oxygen species in patients with nonproliferative diabetic retinopathy and the influence of antioxidant supplementation: 6-month follow-up. Indian J Ophthalmol 2015;63:9-14.
49. [49] Raygan F, Rezavandi Z, Dadkhah Tehrani S, Farrokhian A, Asemi Z. The effects of coenzyme Q10 administration on glucose homeostasis parameters, lipid profiles, biomarkers of inflammation and oxidative stress in patients with metabolic syndrome. Eur J Nutr 2016;55:2357-64.
50. [50] Beal MF. Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases. Biofactors 1999;9:261-6.
51. [51] Galpern WR, Cudkowicz ME. Coenzyme Q treatment of neurodegenerative diseases of aging. Mitochondrion 2007;7Suppl:S146-53.
52. [52] Beal MF. Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Radic Res 2002;36:455-60.
53. [53] Wadsworth TL, Bishop JA, Pappu AS, Woltjer RL, Quinn JF. Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease. J Alzheimers Dis 2008;14:225-34.
54. [54] Shults CW. Coenzyme Q10 in neurodegenerative diseases. Curr Med Chem 2003;10:1917-21.
55. [55] Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-50.
56. [56] Müller T, Büttner T, Gholipour AF, Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett2003;341:201-4.
57. [57] Thomas B, Beal MF. Parkinson's disease. Hum Mol Genet 2007;16 Spec No.2:R183-94.
58. [58] Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 2008;4:600-9.
59. [59] Sutachan JJ, Casas Z, Albarracin SL, Stab BR 2nd, Samudio I,Gonzalez J, et al. Cellular and molecular mechanisms of antioxidants in Parkinson's disease. Nutr Neurosci 2012;15:120-6.
60. [60] Beal MF. Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2009;15Suppl3:S189-94.
61. [61] Yoritaka A, Kawajiri S, Yamamoto Y, Nakahara T, Ando M, Hashimoto K, et al. Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease. Parkinsonism Relat Disord 2015;21:911-6.
62. [62] Li Z, Wang P, Yu Z, Cong Y, Sun H, Zhang J, et al. The effect of creatine and coenzyme q10 combination therapy on mild cognitive impairment in Parkinson's disease. Eur Neurol 2015;73:205-11.
63. [63] Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol 2014;71:543-52.
64. [64] Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol 2007;64:938-44.
65. [65] Negida A, Menshawy A, El Ashal G, Elfouly Y, Hani Y, Hegazy Y, et al. Coenzyme Q10 for patients with Parkinson's disease: a systematic review and meta-analysis. CNS Neurol Disord Drug Target 2016;15:45-53.
66. [66] Zhu ZG, Sun MX, Zhang WL,Wang WW, Jin YM, Xie CL. The efficacy and safety of coenzyme Q10 in Parkinson's disease: a meta-analysis of randomized controlled trials. Neurol Sci 2017;38:215-24.
67. [67] Shoshan-Barmatz V, Nahon-Crystal E, Shteinfer-KuzmineA, Gupta R. VDAC1, mitochondrial dysfunction, and Alzheimer's disease. Pharmacol Res 2018;131:87-101.
68. [68] Ishrat T, Khan MB, Hoda MN, Yousuf S, Ahmad M, Ansari MA, et al. Coenzyme Q10 modulates cognitive impairment against intracerebroventricular injection of streptozotocin in rats. Behav Brain Res 2006;171:9-16.
69. [69] Choi H, Park HH, Koh SH, Choi NY, Yu HJ, Park J, et al. Coenzyme Q10 protects against amyloid β-induced neuronal cell death by inhibiting oxidative stress and activating the P13K pathway. Neurotoxicology 2012;33:85-90.
70. [70] Ha AD, Fung VS. Huntington's disease. Curr Opin Neurol 2012;25:491-8.
71. [71] Jodeiri Farshbaf M, Ghaedi K. Huntington's disease and mitochondria. Neurotox Res 2017;32:518-29.
72. [72] Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57:397-404.
73. [73] McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, et al. Arandomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology 2017;88:152-9.
74. [74] Bartsch H, Nair J. Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch Surg 2006;391:499-510.
75. [75] Akinobu T, Kazuhide Y. Control of oxidative stress in hepatocellular carcinoma: Helpful or harmful? World J Hepatol 2015;7:968-79.
76. [76] Leufkens AM, van Duijnhoven FJ, Woudt SH, Siersema PD, Jenab M, Jansen EH, et al. Biomarkers of oxidative stress and risk of developing colorectal cancer: a cohort-nested case- control study in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol 2012;175:653-63.
77. [77] Jolliet P, Simon N, Barre J, Pons JY, Boukef M, Paniel BJ, et al. Plasma coenzyme Q10 concentrations in breast Cancer; prognosis and therapeutic consequences. Int J Clin Pharmacol Ther 1998;36:506-9.
78. [78] Palan PR, Mikhail MS, Shaban DW, Romney SL. Plasma concentrations of coenzyme Q10 and tocopherols in cervical intraepethilialneoplasia and cervical cancer. Eur J Cancer Prev 2003;12:321-6.
79. [79] Rusciani L, Proietti I, Rusciani A, Paradisi A,Sbordoni G, Alfano C, et al. Low plasma coenzyme Q10 levels as an independent prognostic factor for melanoma progression. J Am Acad Dermatol 2006;54:234-41.
80. [80] Gutierrez-Mariscal FM, Perez-Martinez P, Delgado-Lista J, Yubero-Serrano EM, Camargo A, Delgado-Casado N, et al. Mediterranean diet supplemented with coenzyme Q10 induces postprandial changes in p53 in response to oxidative DNA damage in elderly subjects. Age (Dordr) 2012;34:389-403.
81. [81] Kantor ED, Ulrich CM, Owen RW, Schmezer P, Neuhouser ML, Lampe JW, et al. Specialty supplement use and biologic measures of oxidative stress and DNA damage. Cancer Epidemiol Biomarkers Prev 2013;22:2312-22.
82. [82] Gutierrez-Mariscal FM, Yubero-Serrano EM, Rangel-Zúñiga OA, Marín C, García-Rios A, Perez-Martinez P, et al. Postprandial activation of p53-dependent DNA repair is modified by Mediterranean diet supplemented with coenzyme Q10 in elderly subjects. J Gerontol A Biol Sci Med Sci 2014;69:886-93.
83. [83] Iarussi D, Auricchio U, Agretto A, Murano A, Giuliano M, Casale F, et al. Protective effect of coenzyme Q10 on anthracyclinescardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med 1994;15(suppl):S207-S212.
84. [84] Roffe L, Schmidt, K, Ernst E. Efficacy of coenzyme Q10 for improved tolerability of cancer treatments; a systematic review. J Clin Oncol 2004;22:4418-24.
85. [85] Hill GJ, Shriver BJ, Arnett DB. Examining intentions to use CoQ10 amongst breast cancer patients. Am J Health Behav 2006;30:313-21.
86. [86] Lesser GJ, Case D, Stark N, Williford S, Giguere J, Garino LA, et al. A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. J Support Oncol 2013;11:31-42.
87. [87] SpigsetO. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344:1372-3.
88. [88] Zhou Q, Zhou S, Chan E. Effect of coenzyme Q10 on warfarin hydroxylation in rat and human liver microsomes. Curr Drug Metab 2005;6:67-81.
89. [89] Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy 2007;27:1237-47.
90. [90] Bhagavan HN, Chopra RK. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res 2006;40:445-53.
91. [91] Zmitek J, Smidovnik A, Fir M, Prosek M, Zmitek K, Walczak J, et al. Relative bioavailability of two forms of a novel water-soluble coenzyme Q10. Ann Nutr Metab 2008;52:281-7.
92. [92] Bhagavan HN, Chopra RK. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion 2007;7 Suppl:S78-88.
93. [93] Schulz C, Obermüller-Jevic UC, Hasselwander O, Bernhardt J, Biesalski HK. Comparison of the relative bioavailability of different coenzyme Q10 formulations with a novel solubilizate (Solu Q10). Int J Food Sci Nutr 2006;57:546-55.
94. [94] Liu ZX, Artmann C. Relative bioavailability comparison of different coenzyme Q10 formulations with a novel delivery system. Altern Ther Health Med 2009;15:42-6.